Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid‐responsive hepatitis: report of 22 cases

Abstract

CPA-induced liver injury is severe and can be fatal, and may occasionally resemble autoimmune DILI. The benefit/risk ratio of this drug should be thoroughly assessed in each patient.

When the Creation of a Consortium Provides Useful Answers: Experience of The Latin American DILI Network (LATINDILIN)

“…The second achievement is that, through the establishment of standardized prospective data collection procedures and sample sharing, this registry has enabled delineation of the distinct profile of hepatotoxicity in Latin America caused by specific drugs or herbal and dietary supplements mainly used in this continent, for example, the first description of severe immunological liver damage induced by cyproterone acetate, the analysis of DILI risk induced by coxibs in clinical practice, or the compilation of one of the largest series of nitrofurantoin hepatotoxicity…”

Histopathological challenges in suspected drug‐induced liver injury

“…61 Inflammation that suggests immune-mediated (lymphocytes and plasma cells) or hypersensitivity (granulomas and oeosinophils) injury might be treated with steroids or other immunosuppression. 11,[62][63][64] Cholestatic injury may respond to ursodeoxycholic acid, 65 although it is not clear if either immunosuppression or ursodiol are able to alter the natural history of VBDS. 28 Certain types of injury on biopsy carry prognostic significance.…”

Cuando la creación de un consorcio proporciona respuestas útiles: experiencia de la Latin American DILI network (LATINDILIN)

“…El segundo logro es que, gracias a la instauración de procedimientos estandarizados para recopilar datos prospectivos y compartir muestras, este registro ha permitido dibujar un perfil de hepatotoxicidad propio de Latinoamérica. Este distinto perfil se debe al uso específico de determinados fármacos, hierbas o suplementos dietéticos; aquí tenemos, por ejemplo, la primera descripción de daño hepático inmunológico severo inducido por acetato de ciproterona, el análisis de riesgo de DILI inducido por coxibs en la práctica clínica o la recopilación de una de las mayores series de hepatotoxicidad por nitrofurantoína.…”